Genmab A/S (OTCMKTS:GNMSF – Get Free Report) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $278.91 and traded as low as $265.28. Genmab A/S shares last traded at $265.28, with a volume of 739 shares traded.
Genmab A/S Price Performance
The firm has a 50 day moving average of $261.72 and a two-hundred day moving average of $278.83. The stock has a market cap of $17.27 billion, a PE ratio of 21.87 and a beta of 1.05.
Genmab A/S (OTCMKTS:GNMSF – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported $3.13 earnings per share for the quarter. The business had revenue of $779.50 million during the quarter. Genmab A/S had a net margin of 30.74% and a return on equity of 20.80%.
Genmab A/S Company Profile
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Further Reading
- Five stocks we like better than Genmab A/S
- 3 Warren Buffett Stocks to Buy Now
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- What Are the U.K. Market Holidays? How to Invest and Trade
- MarketBeat Week in Review – 8/12 – 8/16
- Investing in the High PE Growth Stocks
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
